NCT02358031 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02358031
Title	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Recruitment	Completed
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Merck Sharp & Dohme Corp.
Indications	oral squamous cell carcinoma hypopharynx cancer head and neck squamous cell carcinoma laryngeal squamous cell carcinoma oropharynx cancer nasopharynx carcinoma
Therapies	Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin
Age Groups:	adult
Covered Countries

Facility	Status	City	State	Zip	Country	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT02358031Clinical Trial Detail